We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Vectura Group plc has signed an agreement with Monash University’s Institute of Pharmaceutical Sciences (MIPS), to develop inhaled oxytocin delivered via a dry powder inhaler to prevent postpartum hemorrhage (PPH) in childbirth.